Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — To yield the benefits of interventional glaucoma treatment, ophthalmologists need a roadmap for how to implement it, according to a speaker here.
At the Hawaiian Eye 2026 meeting, Christine Funke, MD, said that acceptance of interventional glaucoma (IG) has been a slow process, likely due to lingering doubts about whether it is best for patients.
“I’m starting to wonder: How heavily do we believe in IG? Are we really ‘all in’ as a community, or are we skirting issue and not really using it in practice?” she said. “I think that if you’re not seeing every single patient that